AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Company Overview - AnaptysBio is in the process of spinning off its biopharma operations into a new company called First Tracks Bio, expected to be established in one to two months [2] - AnaptysBio has over 20 years of experience in developing antibodies, with two successful programs: Jemperli (dostarlimab), an oncology drug sold by GSK, and imsidolimab, which has a PDUFA date at the end of the year and is expected to be sold by Vanda [2][3] Current Programs - The company is retaining its name AnaptysBio for the royalty-based financial entity that will hold the two successful programs [3] - In the biopharma segment, AnaptysBio is developing AMB033, a CD122 antagonist for celiac disease and EoE in Phase Ib, and rosnilimab, a PD-1 depleter with positive Phase IIb data in arthritis [3] - AnaptysBio is planning to meet with the FDA this quarter to discuss the next steps for the rosnilimab program and is seeking strategic or financial capital to advance its initiatives [4]